CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Vail Health

Vail Health provides 24/7 hospital, urgent-emergent care, orthopaedics, cardiology, physical therapy, endocrinology, internal medicine, cancer care, childbirth, surgery and plastics.

Phlow

Securing our nation’s pharmaceuticals through U.S. Manufacturing.

Aerodyne Research

Aerodyne Research is a Billerica, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Qosina

Qosina is one of the leading medical device component suppliers of OEM components to medical and pharmaceutical industries. Explore our products today.